PACIFIC-5: A phase III study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)

Basit Öğe Kaydı
dc.contributor.authorWu, Y-L.
dc.contributor.authorWu, L.
dc.contributor.authorBi, N.
dc.contributor.authorCil, T.
dc.contributor.authorGe, H.
dc.contributor.authorZhu, Z.
dc.contributor.authorWang, C-L.
dc.date.accessioned2026-04-04T13:35:13Z
dc.date.available2026-04-04T13:35:13Z
dc.date.issued2024
dc.departmentİnönü Üniversitesi
dc.descriptionEuropean-Society-for-Medical-Oncology Asia Congress (ESMO) -- DEC 06-08, 2024 -- Singapore, SINGAPORE
dc.description.abstract[No abstract available]
dc.description.sponsorshipAstraZeneca
dc.description.sponsorshipAstraZeneca.
dc.description.sponsorshipEuropean Soc Med Oncol
dc.identifier.doi10.1016/j.annonc.2024.10.643
dc.identifier.endpageS1624
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.startpageS1624
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2024.10.643
dc.identifier.urihttps://hdl.handle.net/11616/109699
dc.identifier.volume35
dc.identifier.wosWOS:001401985200400
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofAnnals of Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.titlePACIFIC-5: A phase III study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu